

31 October 2023

Treatment of renal cell carcinoma and melanoma

In order to respond to this request the information below was obtained from RISOH (regional information system oncology & haematology) for the period of time June – August 23

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):

- **Avelumab + Axitinib:** 5
- **Axitinib:** <5
- **Cabozantinib :** 7
- **Everolimus:** <5
- **Lenvatinib + Everolimus:** 6
- **Nivolumab monotherapy:** 12
- **Nivolumab + Cabozantinib:** 12
- **Nivolumab + Ipilimumab:** <5
- **Pazopanib:** <5
- **Pembrolizumab monotherapy:** 20
- **Pembrolizumab + Axitinib:** <5
- **Pembrolizumab + Lenvatinib:** <5
- **Radiotherapy only:** 18
- **Sunitinib:** <5
- **Temsirolimus:** <5
- **Tivozanib:** <5
- **Other active systemic anti-cancer therapy:** <5
- **Palliative care only:** Information not available from RISOH

Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.

Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

- **Cobimetinib:** <5
- **Dabrafenib:** <5

31 October 2023

- **Dabrafenib AND Trametinib:** 8
- **Dacarbazine:** <5
- **Denosumab:** <5
- **Encorafenib AND Binimetinib:** 12
- **Ipilimumab:** <5
- **Ipilimumab AND Nivolumab:** 11
- **Nivolumab:** 14
- **Pembrolizumab:** 49
- **Trametinib:** <5
- **Vemurafenib:** <5
- **Vemurafenib AND Cobimetinib:** <5
- **Other active systemic anti-cancer therapy:** Tebentafusp Map = <5
- **Palliative care only:** Information not available from RISOH

Q3. Does you trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?

The Belfast Health & Social Care Trust can confirm the following trial specific to Renal Cell Carcinoma is scheduled to open from 16 October 2023:

CLIN 6000-452: A Prospective Observational International Study of Cabozantinib Tablets in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma in Adults

The following study is in the set-up phase:

LION: Pan Tumour Trial of Cox-Inhibitor and Immune Checkpoint Blockade

There are also a number of early phase studies that are available to patients with renal cell carcinoma:

Bay 21343: An open-label, Phase 1b, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics and efficacy of the Aryl Hydrocarbon Receptor inhibitor (AhRi) BAY 2416964 in combination with pembrolizumab in participants with advanced solid tumors
No patients recruited to date

Target NATIONAL: Tumour Characterisation to Guide Experimental Targeted Therapy - National Expansion – Prof Vicky Coyle
34 patients recruited to date, none however have been patients with renal cell carcinoma

Determine: An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers with Actionable Genomic Alterations, including Common Cancers with Rare Actionable Alterations

31 October 2023

Opening within the next few weeks